- Home
- ITOS vs MXCT Comparison
ITOS vs MXCT Comparison
Compare ITOS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- MXCT
- Stock Information
- Founded
- ITOS 2011
- MXCT 1999
- Country
- ITOS United States
- MXCT United States
- Employees
- ITOS N/A
- MXCT N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ITOS Health Care
- MXCT Health Care
- Exchange
- ITOS Nasdaq
- MXCT Nasdaq
- Market Cap
- ITOS 270.7M
- MXCT 275.7M
- IPO Year
- ITOS 2020
- MXCT 2021
- Fundamental
- Price
- ITOS $6.67
- MXCT $2.36
- Analyst Decision
- ITOS Strong Buy
- MXCT Strong Buy
- Analyst Count
- ITOS 3
- MXCT 1
- Target Price
- ITOS $25.67
- MXCT $9.00
- AVG Volume (30 Days)
- ITOS 550.0K
- MXCT 734.8K
- Earning Date
- ITOS 04-28-2025
- MXCT 05-07-2025
- Dividend Yield
- ITOS N/A
- MXCT N/A
- EPS Growth
- ITOS N/A
- MXCT N/A
- EPS
- ITOS N/A
- MXCT N/A
- Revenue
- ITOS $35,000,000.00
- MXCT $37,675,000.00
- Revenue This Year
- ITOS N/A
- MXCT $9.05
- Revenue Next Year
- ITOS $31.74
- MXCT $19.98
- P/E Ratio
- ITOS N/A
- MXCT N/A
- Revenue Growth
- ITOS 177.89
- MXCT N/A
- 52 Week Low
- ITOS $4.80
- MXCT $2.21
- 52 Week High
- ITOS $18.75
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- ITOS 49.00
- MXCT 33.78
- Support Level
- ITOS $6.18
- MXCT $2.60
- Resistance Level
- ITOS $7.80
- MXCT $2.86
- Average True Range (ATR)
- ITOS 0.50
- MXCT 0.15
- MACD
- ITOS -0.05
- MXCT -0.02
- Stochastic Oscillator
- ITOS 29.94
- MXCT 9.77
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.